Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease
- 26 October 2010
- journal article
- Published by Springer Nature in Leukemia
- Vol. 25 (1) , 186-189
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Oncogenic Kras Initiates Leukemia in Hematopoietic Stem CellsPLOS Biology, 2009
- Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformationBlood, 2009
- K-RasG12D–induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to γ-secretase inhibitorsBlood, 2008
- Inactivating Icmt ameliorates K-RAS–induced myeloproliferative diseaseBlood, 2008
- Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived CompoundsJournal of Biological Chemistry, 2008
- GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS–induced lung cancerJournal of Clinical Investigation, 2007
- Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative diseaseJournal of Clinical Investigation, 2004
- Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderProceedings of the National Academy of Sciences, 2003
- The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent MannerJournal of Biological Chemistry, 1997